To confirm whether New FP therapy with these characteristics induced step 1 of the cancer-immunity cycle (release of cancer cell antigens upon cancer cell death), we evaluated serum high mobility group box 1 (HMGB1), one of the damage-associated molecular patterns,9 levels one month after New FP therapy. The gene discussed is HMGB1; the disease is cancer.